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An increasing number of genes encoding PLP-dependent transcription regulators and 
MocR/GabR type regulators have been identified in various bacterial genomes. However, only a 
handful of them, including MocR, PdxR, and GabR have been studied experimentally. They 
control different aspects of the bacterial metabolism. Only GabR has a reported crystallographic 
structure. MocR/GabR regulators possess a chimeric structure consisting of a winged helix-turn-
helix (wHTH) DNA binding domain and an aminotransferase-like regulatory domain, which can 
bind PLP as an effector in transcription regulation. Such a chimeric construct presents a 
compelling case in molecular evolution. The regulation domains of all MocR/GabR type 
regulators loss their catalytic capacity during evolution and function as means of effector 
recognition and transcription regulation. A MocR/GabR homolog in Klebsiella pneumoniae has 
recently been studied; this homolog is currently named Duf161R (YczR) since it is putatively 
believed to control a gene encoding a membrane protein annotated as “domain of unknown 
function 161”.  
The three-dimensional crystal structure of the regulatory domain of YczR have been 
determined to a resolution of 1.79 Å. Our crystallographic studies hav revealed the structure of a 
truncated regulation domain with PLP bound, and our spectroscopic studies have collected 
evidence to support at least partial transaminase-like catalytic activity of the regulatory domain. 
Together with DNA binding studies, we provide data on a new case of MocR regulation and its 
currently unconfirmed biological function, which is likely augmenting pathogenesis via  
 xx 
facilitating taurine trafficking in K. pneumoniae.  
Together with DNA binding studies, we provide data on a new case of MocR regulation and 
its currently unconfirmed biological function, which is likely augmenting pathogenesis via 
facilitating taurine trafficking in K. pneumoniae.  
During my Ph.D. program, I also worked on several other protein projects. I have included 
chapter two for the PTP1B project. Protein tyrosine phosphatase 1B (PTP1B) is an enzyme 
shown to play an essential role in insulin regulation. PTP1B is a critical negative regulator of 
insulin and leptin signaling pathways by removing phosphate groups (PO43-) from insulin 
receptor and other post-receptor substrates. Previous studies have identified transition metal 
compounds that exhibit insulin-mimetic effects. A plausible explanation is that vanadium-
containing compounds and zinc-containing compounds inhibit PTP1B activity, which allows the 
required phosphorylation reaction to proceed normally. One specifically modified vanadium-
containing compound has been synthesized. This research has determined the three-dimensional 
crystal structure of PTP1B and VO(acac)2 complex to a resolution of 2.2 Å. Furthermore, the 






YCZR, A NEW CASE OF PLP-DEPENDENT MOCR/GABR TYPE TRANSCRIPTION 
REGULATOR IN KLEBSIELLA PNEUMONIAE 
Research Aims: YczR may be Potential Anti-Virulence Target for Klebsiella pneumoniae 
Klebsiella pneumoniae is a Gram-negative, facultatively anaerobic bacterium[1-3]. It can 
reside in the human flora of the mouth, skin, and intestines[2, 4, 5]. Once aspirated to the lungs, 
specifically to the alveoli, it can cause hemoptysis and destructive changes to human and animal 
lungs[3, 6]. It also can lead to a range of different illnesses, such as wound infections, urinary tract 
infections (UTI), bloodstream infections, meningitis, surgical site infections, and pneumonia[7-9]. 
K. pneumoniae is a multi-drug resistant bacterium and consumes taurine as part of the 
pathogenesis infecting humans. 
Klebsiella infections commonly occur among patients who take long courses of certain 
antibiotics. Patients who have intravenous catheters or are on a ventilator are are also at a higher 
risk of Klebsiella infections[10-14].  
According to the Centers for Disease Control and Prevention (CDC) Healthcare-associated 
Infections (HAI) reports, doctors use several powerful antibiotics, such as polymyxins, 
fosfomycin, and aminoglycosides in conjunction to treat Klebsiella infections. However, 
Klebsiella is increasingly becoming resistant to antibiotics[4]. The highly antibiotic-resistant  






Carbapenem-resistant K. pneumoniae (CR-Kp) is the most common type of CRE. 
According to CDC guidelines, CR-Kp is responsible for approximately 7,900 infections and 520 
deaths each year[16, 17]. Some strains of K. pneumoniae can produce Klebsiella pneumoniae 
carbapenemases (KPC) to render the antibiotics ineffective. KPC-producing bacteria are resistant 
to most classes of known antibiotics, including carbapenems, which are considered as a drug of 
last resort (DoLR) against antibiotic-resistant Gram-negative infections[6, 16]. Drug resistance and 
diminished effect of medication on bacteria and other infectious diseases are becoming one of 
the most significant health issues of the 21st century. To combat this problem, novel 
antimicrobial targets need to be identified[2]. 
Gene Transcription and Transcription Factors 
Gene transcription is fundamentally important for metabolism and normal physiological 
activities at the first step of gene expression. During transcription, RNA polymerase uses a 
particular segment of genomic DNA as a template to synthesize a single-stranded 
complementary mRNA primary transcript[18]. Therefore, transcription is a highly regulated 
process.  
Bacteria adapt to environmental changes by carrying out highly sophisticated responses via 
transcription regulation. Transcription factors (TFs) control transcription regulation by binding to 
specific DNA sequences and leading to either activation or repression of certain genes. TFs 
recognition of specific DNA binding sites is essential for mediating gene expression and 






TFs employ a variety of mechanisms to recognize target nucleotide sequences such as 
hydrophobic contacts and hydrogen bonds between DNA bases and amino acid side chains. They 
can bind to the specific promoter or regulatory regions of DNA by a variety of unique domains 
or motifs such as zinc fingers, leucine zippers, helix-turn-helix (HTH) domains, sheet DNA-
binding proteins, and transcription activator-like effector (TALE) domains. TFs can also 
recognize the local three-dimensional (3D) shape of the target DNA sequence at the protein-
binding site, including sequence dependent narrowing of the DNA minor groove.  
TF’s play several critical biological roles in bacteria, such as basal transcription regulation, 
cell cycle control, intercellular signal response, pathogenesis, environmental response, and 
differential enhancement of transcription[19, 20]. Therefore, TFs are potential antimicrobial targets.  
Based on biophysical, molecular, computational, and X-ray crystallography studies over the 
past decade, scientists have located numerous TFs binding sites, by deducing from aligning a set 
of DNA sequence that is experimentally known[21]. However, understanding the TFs binding 
mechanisms has proven to be a challenge, especially concerning mechanisms details. The 
primary difficulty is in bridging the gap between genomic-scale overview and molecular 
description at molecular level. 
GntR family and the subfamily classification 
The GntR family is a widespread and large group of bacterial TFs. It was named GntR after 
Haydon and Guest had identified and described the first GntR family member the Bacillus 
subtilis gluconate operon repressor in 1991[22]. The database of protein families (Pfam) currently 






PF00392), which spread out among 764 bacteria taxa[23]. In the protein data bank (PDB) the 
metabolite-response GntR family has approximately 106 protein structures been solved.  
GntR family TFs often bind to DNA sequences adjacent to the genes which they control. 
There are many cases in which TFs bind as effectors. In some instances, GntR TFs are also not 
located close to the gene it regulates. One of the well-studied examples is FadR, the 
multifunctional regulator of fatty acid metabolism in E. coli[24].  
The GntR family TFs can regulate various biological processes including metabolism of 
fatty acid, amino acids, utilization of sugars and other carbon sources[22, 25]. Among all bacterial 
transcription regulators, the GntR superfamily proteins are structurally featured by N-terminal 
wHTH DNA-binding domains along with a heterogeneous C-terminal regulatory, effector-
binding/oligomerization (Eb/O) domain, which provides a basis for the constituent subfamilies 
classification.  
While the DNA binding domains in this superfamily share a significant level of similarity, 
as all exhibit the wHTH domain with the canonical HTH motif followed by a beta-turn-beta 
wing hairpin, the C-terminal regulatory ligand binding domains vary significantly. The 
characteristics of the C-terminal domains provide a basis for the current classification of the 
GntR subfamilies: HutC, MocR, YtrA, AraR, DevA, PlmA[26-28] (Figure 1) and, the largest 







Figure 1. Classification of Mycobacterium smegmatis GntR regulators including representatives 
of all subfamily regulators from different bacterial genomes with 1000 bootstrap replicates. All 
the GntR regulators are clustered into six subfamilies. FadR subfamily is branched again into 
two groups (VanR and FadR)[26].  
FadR subfamily is the largest GntR subfamily of all GntR-like regulators. The FadR family 
primarily functions in regulating the expression of enzymes responsible for oxidizing substrates 
related to amino acids, or substrates that emerge from the central metabolism. FadR is named 
after the best-characterized GntR repressor, the acyl-CoA responsive regulator that regulates 
fatty acid metabolism[30, 31]. The crystal structure for FadR of Thermotoga maritima transcription 







Figure 2. Quaternary structure of Thermotoga maritima GntR/ FadR bacterial transcription 
regulator TM0439 (PDB: 3FMS)[32]. 
 
The FadR C-terminal domain characteristically contains 150-160 amino acids, which form a 
six to seven α-helical bundle that binds carboxylic acids and other small organic ligands. A 
unique feature of this family is a kink in helix four which is involved in dimerization.  
 







HutC is the second major GntR subfamily accounts of all GntR-family transcription 
regulators[31]. The HutC C-terminal domain is approximately 170 amino acids in length and 
consists of α-helices and β-sheets [25]. Although the HutC C-terminal domain lacks enzymatic 
activity, it shares a similar fold with chorismate from E.coli; it can bind effectors such as 
histidine, fatty acids, and sugars. This subfamily derives its name from HutC regulator in 
Pseudomonas putida which is involved in regulating histidine utilizing genes[31]. Capable of 
binding to a wide range of effector ligands, HutC regulators are involved in a variety of 
processes such as conjugative plasmid transfer, sensing of nutritional status in the environment, 
and antibiotic production[30, 31]. The X-ray structure of the GntR/HutC bacterial transcription 
regulator YvoA is shown (Figure 3; PDB ID: 2WV0)[33]. 
 
 
Figure 4. Quaternary structure of Corynebacterium glutamicum GntR/ YtrA bacterial 
transcription regulator CGL2947 (PDB: 2DU9). 
Most members of the YtrA subfamily form operons with ATP-biding cassette transport 
systems[25]. This subfamily contains a characteristically short 50 amino acid two helices C-
terminal domain. The short domain suggests that effector ligand binding is not likely without 






identified upstream of regulated operons[30]. Furthermore, the abundance of hydrophobic, 
aromatic, negatively charged, and positively charged residues at the end of the domain suggests 
that dimerization most likely occurs through side-chain-side-chain interactions and salt 
bridges[25]. This hypothesis was verified via the crystal structure of CGL2947 from 
Corynebacterium glutamicum (Figure 4), which showed a homodimer assembly[34].  
MocR/GabR 
MocR/GabR, the last of the major families, is characterized by a large C-
terminal/oligomerization domain with an average of length of 350 amino acids (Figure 5). This 
domain is homologous to type I aminotransferases, which catalyze the formation of α-keto acids 
from amino acids using PLP as a cofactor[25]. GabR from B. subtilis, the representative member 
of this family, regulates γ-aminobutyric acid (GABA) metabolism. GABA is an important carbon 
and nitrogen source. In many bacteria, B. subtilis GABA could act as the sole nitrogen source[35]. 
GabR regulates the gabTD pathway in a PLP and GABA dependent manner (Figure 6). In the 
presence of PLP, GabR will repress its transcription, upon binding to GABA, GabR upregulates 
the gabTD pathway promoting GABA metabolism and glutamate biosynthesis. The gabTD 
pathway consists of two genes, which allow for the use of intracellular GABA to generate 







Figure 5. Quaternary structure of Bacillus subtilis GntR/ GabR bacterial transcription regulator 
GabR (PDB: 4N0B)[36]. 
 
 
Figure 6. Schematic of GabR binding sites at the gabTD and gabR promoters. A schematic of the 
gabR and gabTD gene location is shown here. The arrows indicate the transcription directions 






two direct repeats (ATACCA) are indicated, and the 47-bp GabR binding site (-63 to -17) is 
shown in detail. 
The two genes, gabT and gabD, encode for the enzymes GABA aminotransferase (GABA-
AT) and succinic semialdehyde dehydrogenase (SSADH), respectively. GABA-AT catalyzes the 
ping-pong transamination using GABA as an amino group donor, PLP as a coenzyme, and α-
ketoglutarate as an amino group acceptor. In the first half reaction, GABA donates its amino 
group to PLP forming pyridoxamine 5’-phosphate (PMP) and releases succinic semialdehyde. In 
the second half reaction, PMP donates its amino group to α-ketoglutarate forming glutamate and 
regenerating PLP. Downstream, the GabD succinate semialdehyde dehydrogenase will convert 






PLP Pyridoxal phosphate 
Pyridoxal 5'-Phosphate (PLP) is the active biological form of vitamin B6, which exists in 
the form of six interconvertible vitamers: pyridoxine, pyridoxamine, pyridoxal and their 5’-
phosphorylated forms[38-40]. PLP acts as a coenzyme in a variety of enzymatic reactions in all 
organisms, such as deamination, decarboxylation, racemization reactions of amino acids and in 
vast majority of transamination reactions[41]. 
The Enzyme Commission (EC) has identified more than 145 PLP-dependent activities 
which corresponding to about 4% of all classified activities[42]. Almost 1.5% of genes generally 
encode PLP-dependent enzymes in the free-living prokaryotic genomes[42]. The most common 
PLP-dependent enzymes are phosphorylases, aminotransferases, decarboxylases, glycogen 
amino acid racemases, and enzymes catalyzing β- or γ-elimination or replacement. The utility of 
PLP lies in its ability to stabilize carbanionic reaction intermediates by acting as an electrophilic 
catalyst after covalently binding to substrates. PLP is also involved in stress responses, especially 
to oxidative stress, which can quench reactive oxygen species[43]. The dysregulation of PLP 
metabolism can cause various physiological deficiencies, such as reduced glucan production, 
lowered stress tolerance, growth inhibition and biofilm formation[43].  
Some PLP-dependent enzymes generate enamine/imine intermediates that can inactivate 
other enzymes by covalent binding to their active site, whereas the RidA-family proteins quench 
these reactive intermediates to prevent metabolic damage[44].  
The PLP aldehyde group can form a Schiff base linkage (internal aldimine) with the ε-






transaldimination, the amino acid substrate α-amino group displaces the ε-amino group of the 
active-site lysine. And then, the external aldimine can lose a proton, an amino acid side chain or 
carbon dioxide to form a quinoid intermediate, which can act as a nucleophile in several reaction 
pathways[38, 45, 46]. 
Domain of unknown function 
Domains of unknown function (DUF) are a large set of uncharacterized protein families that 
are found in the Pfam database that has no characterized function[47, 48]. More than 20% of all 
protein domains in the protein family’s database were annotated as DUFs in 2013[49]. The 
number of DUFs is substantially increased with the rapidly accumulating genome sequencing 
data[47]. These genes have been collectively given in the Protein family’s database the prefix 
DUF followed by a number. Some DUFs are highly conserved, indicating an important role in 
biology. However, the biological function of many DUFs often remains unknown because such 
proteins are not essential[48, 49]. Structural genomics program has attempted to understand the 
function of DUFs through structure determination. The structure of more than 250 DUF families 
proteins have been solved[49]. These protein families have been collected together in the Pfam 
database using the prefix DUF followed by a number. There are over 3,000 DUF families in the 
Pfam database representing over 20% of known families[49]. 
DUF161 is an uncharacterized hypothetical membrane protein, belonging to YitT family. 
This entry describes proteins with a trans-membrane domain. The functions of this family are 






proteins. Membrane proteins have proven to be challenging to study owing to their flexibility, 
partially hydrophobic surfaces, and lack of stability[50].  
MocR/YczE 
Generally, YczE and YitT family protein have been annotated as “membrane proteins 
containing the DUF161 domain”. YczR, in K. pneumoniae, is the transcriptional regulator of 
DUF161. The crystal structure of YczR would provide information to speculate on the function 
of DUF161. 
The TF of yczE genes, named YczR, predicted to constitute a MocR subfamily. Bacterial 
YczE family proteins are predicted to be unknown function membrane proteins which prosessing 
five trans-membrane helices. Based on the Conserved Domain Database (CDD), code COG2364 
belongs to the YczE family. Corresponding to the Pfam database (code: PF02588), InterPro 
databank (code IPR003740), and CDD (code COG1284), YczR and YitT family shared the 
presence of DUF161 domains. Based on the annotations report of the databanks, YczE and YitT 
family do not have apparent differences[51]. Possibly, they may be distinguished by the absence 
of the C-terminal DUF2179 domain in YczE, corresponding to the Protein Data Bank (PDB) 
structure PDB: 3HLU, present in the members of the YitT family[51, 52].  
YczR, in K. pneumoniae, is the transcriptional activator of YczE, which belongs to the 
transcriptional regulator MocR family. It is supposed to regulate the expression of the yczE 
genes. MocR regulators are a subfamily belonging to the class of GntR regulators characterized 






regulatory domain. The C-terminal domains belong to the superfamily of the PLP enzymes of the 
fold type I[53].  
Two members of the MocR/GntR family have been characterized in detail, GabR, and PdxR. 
GabR positively regulates the expression of the gabTD operon, which is responsible for the 
utilization of gamma-Aminobutyric acid[36, 54]. PdxR regulates the expression of the pdxST 
genes[55].  
Obtaining the structure of YczR will help us in speculating the function of YczE. In our 
current research, we have solved the K. pneumoniae YczR regulator domain crystal structure and 
apo-YczR crystal structure. Based on the structure, we speculate that YczR might have a half 
alanine-glyoxylate transaminase activity. Based on this speculation, we designed the UV-
absorption spectroscopic measurements, end-point enzymatic assays, and fluorescence 
spectroscopy. Alanine-glyoxylate aminotransferase catalyzes the transfer of the L-alanine to 
glyoxylate, forming glycine and pyruvate. In the first half-transamination reaction, L-alanine 
reacts with the pyridoxal form of the enzyme to yield the pyruvate and the pyridoxamine form of 
the enzyme[56-60]. We also used size exclusion chromatography with multi-angle light scattering 
(SEC-MALS), small-angle x-ray scattering (SAXS), mass spectrometry, and transmission 
electron microscopy (TEM) methods to gain an in-depth understanding of the characteristics of 
YczR and valuable clues for the function of YczE. We used fluorescence polarization assay to 
determine the YczR binding DNA sequence. Fluorescence polarization assays are suitable for the 
analysis of binding between the small fluorescence-labeled DNA fragment and its significantly 




CRYSTAL STRUCTURE OF KLEBSIELLA PNEUMONIAE YCZR, THE 
TRANSCRIPTIONAL REGULATOR OF THE DOMAIN OF UNKNOWN FUNCTION 161 
(DUF161) 
Research Significance 
YczR is a member of the understudied MocR/GabR subfamily of the GntR family of 
transcription regulators. A Typical GntR/MocR subfamily protein contains a large C-terminal 
putative type I aminotransferase domain and a small N terminal wHTH DNA binding domain [25, 
35].  
In the present study, we report two K. pneumoniae YczR regulator domain crystal 
structures: a 1.79 Å structure of YczR with PLP bound and the 2.0 Å apo structure of YczR 
regulator without PLP. We also used size exclusion chromatography with multi-angle light 
scattering (SEC-MALS), small-angle x-ray scattering (SAXS), and mass spectrometry methods 
to gain an in-depth understanding of the biological assembly of YczR. To our best knowledge, 






YczR is a Homodimer 
The YczR protein of K. pneumoniae has a predicted size of 475 amino acids and a 
theoretical molecular mass of 52.25 kDa. YczR was eluted as one major peak on a Superdex 200 
gel-filtration column during protein purification, with an apparent molecular weight of a dimer 
(108 kDa), indicating a dimer of YczR in solution (Figure 7). 
 
 
Figure 1. The gel filtration purification profile of YczR. The YczR major peak (fractions B9-
B12) on Superdex 200 16/60 corresponds to an apparent molecular weight of a dimer.  
YczR crystallizes as a homodimer with the two AT-fold domains organized in a head-to-
head domain arrangement (Figure 8 & 9). As seen in all type I aminotransferases[62, 63], this 
interface of YzcR contains two PLP-binding pockets bound by one molecule of PLP in each 
pocket. The large dimer interface between the two AT-domains further suggests that any such 







Figure 2. Quaternary structure of K. pneumoniae YczR regulator domain. YczR should be a 
head-to-tail domain-swap homodimer. The AT-fold domains are shown in red and blue. An 








Figure 3. Quaternary structure of K. pneumoniae YczR regulator domain. The structure is rotated 
90° counterclockwise along the y axis relative to Figure 8.  
The structure of YczR was solved by molecular replacement and refined to 1.79 Å 
resolutions. The final model contains 385 residues, yielding a crystallographic R-value of 
19.11% and an R-free value of 22.84% with near ideal chemical geometry. Two molecules in an 
asymmetric unit formed a homodimer. Two active sites at the interface of the subunits are shown 






PLP is Bound in the C-terminal AT-Fold Domain 
Based on the amino sequence, the YczR should have a short N-terminal wHTH DNA-bing 
domain and a long C-terminal PLP-binding putative aminotransferase domain. However, the N-
terminal wHTH DNA-binding domains have not been found in YczR crystal structure. We 
speculated that we lost the DNA-binding domain when we purified the protein or during 
crystallization. The regulation domain structure still provides insights into YczR funcations.  
PLP is bound to the C-terminal regulator Domain (Figure 10). The PLP binding pocket also 
corresponds to the cofactor binding sites in the related enzymes and therefore defines the active 
site of YczR. 
 
Figure 4. Quaternary structure of YczR AT-fold domain monomer. PLP is bound in the AT-fold 
domain of YczR. Side chains of the key residues that interact with PLP are shown in stick 







Figure 5. Structure of YczR regulator domainPLP-binding pocket. The residues with 4 and 5 Å 
from K311-PLP were labeled. The PLP and surrounding side chains are shown as sticks. Carbon 
atoms are shown in gray, oxygen atoms in red, and nitrogen atoms in blue. 
One molecule of PLP forms an internal aldimine with the ω-amino group of K311 per YczR 
monomer. As with other types I aminotransferases[62, 63], the YczR AT-fold domain has two 
subdomains, the small subdomain that typically interacts with the α- carboxylate group of the 
substrate and the large subdomain containing the invariant lysine (K311) that forms the Schiff 
base with PLP. The interaction between the ASP278 and pyridine nitrogen of PLP probably 
could protonate the pyridine nitrogen. Although the effectors were unknown, those structure 
features remain.  
In amino transferase reaction, the principal function of PLP is to stabilize the negative 






of the transition state by delocalizing the negative charge through the π-electron system of the 
cofactor[36].  
The YczR AT-fold domain residues that interact with PLP are shown (Figure. 11): The C4A 
atom of PLP is covalently attached to the LYS311 through the formation of an internal Schiff 
base. The PLP-pyridine ring stacked with residues Tyr-201 by formed pi-pi hydrophobic 
interactions. The C2A atom of PLP exhibits hydrophobic interaction with a Met-245 side chain. 
The phosphate group of PLP forms hydrogen bonds and salt bridges with Ser-308, Ala-176, and 
Arg-318. The side chains of Thr-280, Asp-278 and Asn-250 are hydrogen bonded to N-1 and O-
3 of the PLP-pyridoxal, respectively. The phosphate moiety of the PLP formed hydrogen bonds 
with the peptide side chains of residues Arg-318 and Ala-176. This conformation allows 
hydrogen bond with the Lys-311 and could also interact with the amino group from the 







Figure 6. PLP binding pockets. (A) A surface-coated YczR(blue) is shown with the PLP product 
as sticks (carbons colored gray, oxygen colored red and nitrogen colored blue). The PLP is 
buried below the surface. (B) A rotated, cut-away view of panel A, showing a defined pocket for 
binding the PLP, while the opened ring is pointing toward the solvent. 
Compared with the structure of GabR, PLP binding pocket in the YczR AT-fold domain has 
bigger size of the opening (Figure 12). PLP is buried below the surface of the protein. Once the 
internal aldimine between PLP and the K311 broken, the molecular PLP or PMP would be 








Figure 7. Comparison of the structure of K. pneumoniae YczR with B. subtilis GabR (PDB ID: 
4N0B). An orthogonal view of the GabR structure is shown in pink. An orthogonal view of the 
YczR AT-fold domain is shown in blue. 
The crystal structures of K. pneumoniae YczR and B. subtilis GabR (PDB ID: 4NOB) were 
compared to analyze the difference in the overall structure (Figure 13). The YczR AT domain 
size was very similar to that B. subtilis GabR reported. GabR has a long linker connecting C-
terminal AT-fold domain to the N-terminal winged-helix domain. YczR lost the N-terminal 






Structure of Apo-YczR 
We also attempted to get YczR with L-alanine co-crystal. In the resulting crystal structure, 
PLP is no longer bound in the PLP-binding pocket. The PLP-binding site of the crystal structure 
of apo-YczR is shown (Figure 14). The purified YczR protein is pale yellow, which suggested 
that endogenous PLP from E. coli bound to YczR after purification. After co-crystallization of 
YczR and L-alanine, the apo-YczR crystal is clear in color. This result indicated that Schiff base 
between the invariant lysine (Lys-311) and PLP had been broken. 
 
Figure 8. Quaternary structure of apo-YczR AT-fold domain. PLP is no longer bound in the 






One small molecular binds with Ser-308. Apo-YczR crystal crystallization solution 
contained 8% (V/V) Tacsimate, pH 6.0. Tacsimate is a unique crystallization reagent, which is 
composed of a mixture of titrated organic acid salts, developed exclusively by Hampton 
Research. Tacsimate contains malonic acid, ammonium citrate tribasic, succinic acid, DL-malic 
acid, sodium acetate trihydrate, sodium formate, and ammonium tartrate dibasic. We cannot 
jump to the conclusion that L-alanine replaced PLP. We still need to get the same structure result 
from crystallization solution without Tacsimate.  
The crystal structures of YczR-PLP and apo-YczR were compared to analyze the difference 
in the overall structure (Figure 15). The obtained apo-YczR structure with no PLP bound has a 
similar overall conformation when compared to YczR-PLP. The overall similarity suggests that 
the apo-YczR AT-fold domain maintains the overall structural integrity even when PLP is no 







Figure 9. Comparison of the YczR-PLP and apo-YczR AT-domain. The YczR-PLP structure is 







Table 1. Crystallographic data collection and refinement statistics for YczR and Apo-YczR 
 YczR Apo-YczR  
Data Processing 
Space group C2221 C2221 
Cell dimension   
α, β, γ (deg) 123.482, 181.139, 108.567 123.24, 180.005, 106.006 
a, b, c (Å) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 1.82 2.46 
Resolution at I/σ (I) =2 1.85 2.73 
Rpim a (%) 2.9(38) 5.5(60) 
I/σ (I) 25.5(13.4) 13.2(10.9) 
CC ½ b 0.757 0.575 
Completeness (%) 99.4(91.7) 99.7(97.3) 
Multiplicity   
No. Reflections 110262  
No. Unique Reflections  45635  
Refinement 
   
Rwork c/Rfree d(%) 17.64/21.13 20.8/28.96 
No. of Atoms   
protein 8448 8001 
ligand  60 30 
water 650 152 
B factors (Å2)   
protein 30.0 48.912 
ligand   
RMSD e   
bond lengths (Å) 0.02 0.01 
bond angles (deg) 2.07 1.67 
Ramachandran plot (%)   
most favored   
allowed   
outliers   
aPrecision-indicating merging R  
bPearson correlation coefficient of two “half”data sets   
cRwork = Σ|Fobs − Fcalc|/ΣFobs 
dFive percent of the reflection data were selected at random as a test set, and only these data were used to calculate Rfree 








To determine at which step the DNA-binding domain of YczR was lost, mass spectrometry 
is used to determine the molecular weight of YczR monomer (Figure 16) immediately after 
FPLC purification. YczR monomer has 474 amino acids, which theoretically molecular weight is 
52,112 Da. In the absence of PLP, the Mass Spectrometry plot shows a predominant peak at 
52933 Da, which suggesting a full-length of YczR in solution after FPLC purification. We 
speculate that protein lost N-terminal winged-helix domain during crystallization step. 
 
Figure 10. Mass spectrometry data of YczR-PLP monomer. 
To determine if YczR is a dimer in solution, SEC-MALS was used to assay YczR oligomers 






by Abs280. The molecular weight of 121 ± 5 kDa for this peak is determined by light scattering, 
which matches the mass calculated for the dimer from the expected sequence (52112 Da × 2 = 
104224 Da). YczR came out to be pretty homogeneous with small levels of aggregates that 
eluted right before the main peak and hence, may lead to an overestimation of the molecular 
weight of the main peak. Therefore, speculate YczR even at very low protein concentration still 
forms a dimer that appears a little bigger in solution. SEC-MALS data do not show YczR 
tetramers or higher oligomers exist in solution; however, further YczR oligomerization may still 
occur when the protein binds to DNA.  
 
Figure 11. Molecular weight determinations of YczR in solution. SEC-MALS profiles are shown 
for YczR. The absorbance at 280 nm is shown as a black line, and the calculated molecular 
weight for protein in the eluent at a particular time is shown in color, as noted. YczR (molecular 







Figure 12. The overall comparison of K. pneumoniae YczR and B. subtilis GabR (PDB ID: 
4N0B) SAXS models. 
Both YczR and GabR belong the MocR/GabR subfamily of GntR family of transcription 
regulator[36]. The SAXS model of K. pneumoniae YczR and B. subtilis GabR (PDB ID: 4NOB) 
(Figure 18) were compared to analyze the difference in overall size. Based on the SAXS model 
comparison result, the volume of YczR dimmer in solution was bigger than GabR. The result 
suggested that YczR was containing the much extensional DNA-binding domain. The whole 
structure of YczR should be more extensional.  
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CHAPTER THREE 
YCZR REGULATION DOMAIN CATALYZES A REVERSIBLE HALF-TRANSAMINASE 
REACTION INSTEAD OF BEING A NON-ENZYMATIC REGULATOR LIKE GABR 
The crystal structure of YczR showed that PLP was bound to the regulator domain reacted 
with the lysine (Lys-311) to form a stable internal aldimine, which likely controls the 
transcription from the yczE promoter in K. pneumoniae. 
Alanine-glyoxylate aminotransferase catalyzes the transfer of the amine of L-alanine to 
glyoxylate, forming glycine and pyruvate. In the first half-transamination reaction, L-alanine 
reacts with the pyridoxal form (PLP) of the enzyme to yield the pyruvate and the pyridoxamine 
form (PMP) of the enzyme[56-60]. Based on comparison of the crystal structure of YczR with 
alanine-glyoxylate transaminase structure, we speculated that YczR possibly possess half of the 
alanine-glyoxylate transaminase activity. To test this speculation, we designed the UV-
absorption and fluorescence spectroscopic experiments, and end-point enzymatic assays.  
UV Absorption 
 To test potential YczR substrates, we designed UV-Vis spectroscopy experiments in which 
20 amino acids and other possible substrate were added to the protein.  
The UV absorption of YczR alone in the reaction buffer (50 mM HEPES, pH 7.5, 300 mM 
NaCl) has two peaks maximum at 320 nm and 425 nm (Figure 19). The absorption curve stayed 






formed between an active-site lysine residue of the protein and PLP (Figure. 19, A) are generally 
ascribed to a ketoenamine tautomer, enolimine tautomers, a substituted aldamine respectively or 
PMP[64-68]. The peak at 420 nm signifies the formation of internal aldimine between an active-
site lysine residue of the protein and PLP.  
 
Figure 1. Time-resolved UV absorption spectra of YczR. 6 µM YczR in buffer (50 mM HEPES, 
pH 7.5, 300 mM NaCl) containing 6 µM PLP was taken at 25°C in the absence (A) or presence 
(B) of 500 mM L-alanine. After the addition of L-alanine, UV spectra were taken for 192 
minutes at 2 mins intervals. 
Upon mixing the YczR with 500 mM L-alanine, a biphasic spectral change was observed as 
shown (Figures 19, B). In a time-dependent manner, a slow decrease in the 425 nm peak with a 
concomitant increase in the absorbance at 325 nm was observed within 192 minutes.  
Decrease of the absorption peak at 425 nm and increased that at 330 nm is consistent with 
PLP turning into PMP. We speculated that L-alanine reacted with PLP to form one of the 
intermediates of the half-transamination.  






absorption spectra of YczR-PLP showed an increase in absorption in the range of 300-320 nm in 
reaction with L-alanine (Figure 19, B), suggesting the formation of PMP and possibly pyruvate, 
which both has absorpt at 320 nm. 
To prove one of the products was pyruvate, we added 100 mM pyruvate into the reaction 
cuvette after YczR and L-alanine reaction completed (Figure 20, A). Upon addition of pyruvate, 
the maximum absorption at 320 nm decreased (Figure 20, B). Moreover, maximum absorption at 
425 nm increased at the same time (Figure 20, C). The absorption change suggested that 
pyruvate was a product of PLP and L-alanine reaction. High concentration of pyruvate prompted 
the product from the first half reaction (PMP) reacted with pyruvate producing L-alanine. The 
increase in the UV absorption at 425 nm was observed during the addition of pyruvate, which 
confirms the formation of the Schiff base (aldimine) between PLP and an active-site lysine 
residue of the YczR. It is likely that that PLP-L-alanine reaction is a reversible reaction. Once the 
concentration of the product is increased, it will promote PLP formation.  
 
Figure 2. UV absorption spectra of YczR-L-alanine with pyruvate. Reaction of 6 uM YczR and 
30 mM L-alanine should be completed in 192 mins. 100 mM pyruvate was added into the 
cuvette. UV absorption was measured for 2 hours. Figures shown are for UV absorption change 
in 300 nm-600 nm (A), 306nm-330nm (B) and 400-450 nm (C). Brown line indicates absorption 






Specificity test of YczR with amino acids or small molecular 
 
Figure 3. Specificity test of YczR with amino acids or other small molecules. Shown are UV 
absorption changes of 7 µM YczR in the presence of 300 mM Arginine (A), Lysine (B), Serine 








Figure 4. Specificity test of YczR with amino acids or other small molecules. Shown are UV 
absorption changes of 7 µM YczR in the presence of 300 mM phenyalanine (A), threoine(B), 










Figure 5. Specificity test of YczR with amino acids or other small molecules. Shown are UV 
absorption changes of 7 µM YczR in the presence of 300 mM β-Alanine (A), GABA (B), 









Figure 6. Specificity test of YczR with amino acids or other small molecules. Shown are UV 
absorption changes of 7 µM YczR in the presence of 300 mM histidine (A), tyrosine (B), glycine 







Figure 7. Specificity test of YczR with amino acids or other small molecules. Shown are UV 
absorption changes of 7 µM YczR in the presence of 300 mM aspartic acid (A), asparagine (B), 
proline (C) and D-alanine (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM 
NaCl. 
The UV-visible spectrum of YczR reacted with other amino acids, and possible substrates 
were recorded (Figure 21-25). The time-dependent UV absorption of 7 µM YczR-PLP with 300 
mM Β-Alanine, serine, arginine, lysine, tyrosine, histidine, aspartic acid, phenylalanine, leucine, 
proline, threonine, valine, GABA, tryptophan, asparagine, methionine, and glutamine was 






occurred with the addition of L-alanine were not observed when other amino acids, such as the 
D-alanine, glycine, glutamine or asparagine, were added. The results suggest that YczR 
specifically reacted with L-alanine, which matches the purpose of YczR as it activates 
transcription of the yczE operon. L-alanine or molecules with similar structure may regulate 
YczR function though reaction with PLP.  
Fluorescence emission spectra 
More information about conformational changes of the Schiff base after addition of L-
alanine can be obtained by fluorescence emission spectroscopy.  
Time-dependent fluorescence emission spectra results of YczR with L-alanine is shown 
(Figure 26). YczR (6 µM) and L-alanine (500 mM) were mixed in buffer (50 mM HEPES, pH 
7.5, 300 mM NaCl) at 25 °C. After the addition of L-alanine, fluorescence spectra was taken for 
20 mins at 4 mins intervals. When L-alanine-reacted YczR was excited at 283 nm, the 
characteristic emission peaks of the Shiff base between PLP and lysine were observed at 







Figure 8. Fluorescence emmission spectra of YczR. Fluorescence spectra of YczR-PLP (1.4 µM) 
in the buffer (50 mM HEPES, pH 7.5, 300 mM NaCl) was taken at 25°C in the absence of 500 
mM L-alanine at an excitation wavelength of 283 nm. 
Upon mixing the YczR with L-alanine, a change in fluorescence spectra was observed. The 
peak in the absorbance at 326 nm decreased slowly. The 326 nm absorption peak of the L-
alanine-reacted YczR can be ascribed to the external Schiff base associated with L-alanine. 
These results suggest that the Shiff base formed between PLP in YczR was broken in the 
presence of L-alanine.  






observed when other amino acids, such as the D-alanine, glycine, glutamine or asparagine, were 
added.  
Based on the results of Fluorescence emission spectra and UV absorption spectra, we 
speculate that the internal aldimine of YczR can react with L-alanine specifically.  
An End-point Assay to Monitor the YczR Catalyzed Half Transaminase Reaction 
Based on the UV absorption spectra result, we speculate that L-alanine formed pyruvate 
after reaction with PLP. An End-point assay was designed to confirm this hypothesis (Scheme 1). 
YczR was incubated with L-alanine excess and coupled with a lactate dehydrogenase to monitor 
the consumption of the NADH at 340 nm.  
 
 
Scheme 1. The end-point YczR-catalyzed half-aminotransferase reaction. The first half reaction 
(L-alanine to pyruvate) of the YczR-catalyzed transamination is shown on the top. The second 
























To let the L-alanine and PLP reaction to be completed, 1 µM, 3.5 µM and 7 µM YczR had 
been added in the reaction buffer containing 500 mM L-alanine, 50 mM HEPES, (pH7.5), 300 
mM NaCl, which was kept at room temperature for 15mins. The lactate dehydrogenase 
consumed all pyruvate in each reaction solution to produce lactate. The data above shows 
measured absorbance change at 340 nm from the concomitant oxidation of the cofactor, NADH 
to NAD+. 
The concentrations of protein should affect the starting absorption points. The higher 
concentration of YczR in reaction solution had a higher starting absorption point. The absorption 
of 1 µM, 3.5 µM and 7 µM YczR decreased by 0.01, 0.05 and 0.1, absorption units (Figure 27). 
Those results suggest that 1 µM PLP in the YczR solution could react with 1 µM L-alanine to 
produce 1 µM pyruvate. In the YczR-catalyzed first half aminotransferase reaction, PLP and 
PMP are in dynamic equilibrium when pyruvate is present. All of the PLP was converted to PMP 








Figure 9. An end-point assay to monitor catalysis of half transaminase reaction by YczR. 
Absorption changes of NADH in the presence of 1 µM (blue), 3.5 µM (red) and 7 µM (black) 
YczR. 1 µM, 3.5 µM and 7 µM YczR has been added in the reaction buffer containing 500 mM 
L-alanine, 50 mM HEPES, (pH7.5), 300 mM NaCl, which was kept at room temperature 12 
hours. The lactate dehydrogenase consumed all pyruvate in each reaction solution to produce 
lactate. Absorbance change at 340 nm from the concomitant reduction of the cofactor, NADH to 
NAD+ was measured. 
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CHAPTER FOUR 
YCZR BINDS DNA SEQUENCE BETWEEN YCZR GENE AND YCZE GENE IN A 
SIMILAR FASHION TO GABR 
YczR Binds DNA with High Affinity 
YczR DNA binding sites and binding affinity was determined via fluorescence polarization 
(FP) experiments[70]. The K. pneumoniae YczR regulatory region contains 88 bp and has two 5bp 
direct repeats (CCTCA & AATGG). 
5’ATTTTTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGGACTG
ATAATTAATGGCCAGTTTTGGAAAAGTGGATCGCT3’ within this fragment, the two 
direct repeats of sequences CCTCA and AATGG, appear to be likely for YczR binding. The 
bindings sites between CCTCA and AATGG repeats are separated by 34 bp, which corresponds 
to approximately three helical turns of DNA. Therefore, the corresponding nucleotides of the 
binding sites should lie on the same face of the DNA helix.  
GabR protected a 49 bp region of DNA identified previously for GabR-dependent 
regulation in vivo[35, 36]. Sequence alignment results indicate that many residues of the DNA 
binding regions between GabR and YczR are conserved (Figure 28). The GabR and YczR DNA 
binding regions are similar in type, direction, and spacing. We predict that some protein-DNA 
interactions between GabR-DNA and YczR-DNA complexes will be similar. Although a 
multitude of GntR family DNA bindings sites has been determined, the studies did not indicate a 






Based on the pair of two direct sequence repeats, two 68-bp complementary single-stranded 
DNA oligonucleotides containing the YczR binding region 
(5'TTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGGACTGATAATTA
ATGGCCAGTTTT-TAMRA-3', where Fl means fluorophore) were purchased from Integrated 
DNA Technologies (IDT). Fluorescence polarization assay studies were conducted to estimate 
1nM as the optimal DNA concentration for further experimentation.  
 
Figure 1. Sequence alignment of the winged-helix domain sequences of B. subtilis GabR gabR-
gabT DNA binding regions (top) and K. pneumoniae YczR yceE DNA binding regions (bottom). 
The black asterisks highlight DNA-binding residues of YczR that are identical or similar in 
GabR. 
The binding affinity of YczR for DNA containing the 68-bp YczR binding site was 
determined by FP (Figure 29). Different concentrations of YczR were incubated with TAMRA-
labeled DNA fragments containing the promoter regions of yczE and assayed for the formation 
of protein-DNA complexes. The result showed a dose-dependent polarization increase, indicative 
of YczR binding to DNA. The fluorescence polarization data set was fitted into the modified Hill 
equation to determine the apparent dissociation constant of the YczR-DNA complex, as 26.47 
nM. 






negative control assay was performed with Bovine Serum Albumin (BSA) and the TAMRA-
labeled DNA (Figure 30). A constant concentration of TAMRA-labeled DNA was incubated in 
several aliquots with increasing concentrations of BSA protein. The fluorescence polarization did 
not show any significant change with increasing concentration of BSA, which suggests that 









Figure 2. Fluorescence polarization assays to measure DNA binding by YczR. Titration of YczR 
against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM. The 
average values and errors were plotted and fitted to the Hill equation. Each data point was 
measured in triplicate. Error bars are too small to be displayed if the errors are less than 







Figure 3. Specificity test of YczR fluorescence polarization assays. In the negative control 
binding assay, the same increasing concentrations BSA were used against a fixed concentration 






YczR likely binds to the regulation region with a 2:1 stoichiometry 
Based on the CCTCA and AATGG direct repeats on the DNA sequence, two 34-bp 
complementary single-stranded DNA oligonucleotides containing the YczR binding region 
DNA_1 (5'- TTTCCTCAACATCATTGCGAATGCCCTCATCATTC-TAMRA-3') and DNA_2  
(5'- AGCAAAAATGGACTGATAATTAATGGCCAGTTTT-TAMRA-3') were designed and  
purchased from IDT. The two 34 bp DNA fragment located within the YczR protected region is 
close in size to a minimal fragment allowing YczR binding in vitro.  
YczR binds tighter to the site closer to yczE gene 
DNA_1 has one specific binding site for YczR (Figure 31). The dissociation constant (Kd) 
of the YczR with DNA_1 complex was determined to be 135.1 nM. DNA_2 also has one 
specific binding site for YczR (Figure 32). The dissociation constant (Kd) of the YczR with 
DNA_2 complex was determined to be 33.63 nM. We speculate that YczR binds on the DNA_2 









Figure 4. Fluorescence polarization assays to measure DNA_1 binding by YczR. Titration of 
YczR against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM. 
The average values and errors were plotted and fitted to the Hill equation. Each data point was 
measured in triplicate. Error bars are too small to be displayed if the errors are less than 








Figure 5. Fluorescence polarization assays to measure DNA_2 binding by YczR. Titration of 
YczR against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM. 
The average values and errors were plotted and fitted to the Hill equation. Each data point was 
measured in triplicate. Error bars are too small to be displayed if the errors are less than 






Materials and Methods 
Materials 
Chemicals for YczR purification, crystallization, assays were purchased from Sigma-
Aldrich (St. Louis, MO), Alfa Aesar (Tewksbury, MA) and Fisher Scientific (Pittsburgh, PA). 
YczR gene was synthesized with codon optimization for E. coli expression from Integrated DNA 
Technologies (Coralville, IA).  
E. coli BL21 (DE3) cells and Turbo cells were purchased from New England BioLabs 
(Ipswich, MA). Bacterial growth media Luria-Bertani (LB) broth and antibiotics were obtained 
from Sigma-Aldrich. Crystallization screen solutions and other crystallization supplies were 
purchased from Hampton Research (Aliso Viejo, CA) and Emerald Bio (Bedford, MA). All other 
materials were purchased at the highest quality available. DNA and protein sequences were 
analyzed using DNA Strider and the BLAST program[72, 73].  
Methods 
DNA Cloning. To construct the His-tagged version of the YczR protein, the coding region 
was amplified by PCR from the synthesized YczR gene for K. pneumoniae genomic DNA using 
the specific oligonucleotides as primers (forward primer designed as 
GAAGGAGATATACATATGATCGACCAGAGCGATTGGATA and the reverse primer 
designed as GTGATGGTGGTGATGATGATCCCCTGTAACGGGGATTTT). The PCR 
thermocycler program used included an initial denaturation for 120 s at 95 °C; 40 cycles of 95 °C 
for 30 s, 50 °C for 60 s, and 72 °C for 50 s; and the final extension of 72 °C for 5 min. The PCR 







The YczR DNA fragment was cloned into the NdeI site of pETite by treated with Phusion 
HF DNA polymerase, following the manufacturer's instructions. The pETite-kan-c-5His vector 
with K. pneumoniae YczR full-length gene was transformed insert into E. coli Turbo competent 
Cell (New England Biolabs).  
After pETite-kan-c-5His vector was purified from E. coli Turbo cell, the resulting plasmid 
was then transferred to competent E. coli BL21DE3 cells to overexpress the YczR protein. 
Digestion of the plasmid from E. coli Turbo cell was by DNA Restriction enzymes NdeI and 
NotI. The restricted DNA fragments were analyzed by agarose gel electrophoresis according to 
standard protocols. 
The purified plasmid from BL21DE3 cell was then sent to sequencing. DNA sequencing 
result from DNA Sequencing & Genotyping Facility (University of Chicago Comprehensive 
Cancer Center) confirmed the correct orientation with a C-terminal His6-tag.  
Protein Purification. The YczR protein from E. coli was expressed and purified by using 
the intein-mediated purification with an affinity histidine tag system. Transformed E. coli 
BL21DE3 cultures were grown overnight at 37°C and 250 rpm in 500 ml of LB medium 
containing 50 µg/ml kanamycin.  
Induction of YczR expression was carried out at OD600 of 0.8 by adding Isopropyl-β-D-
thiogalactopyranoside (IPTG) to the final concentration of 0.5 mM.  
Cells were incubated at 25 °C and harvested after 16 hours by centrifugation at 7000 RPM 






resuspended in Ni column buffer containing 5% (vol/vol) glycerol and 1 mM PLP. 
Following sonication (Qsonica sonicators, Q500 Sonicator) to break the cellular wall, the 
cell extract was cleared by centrifuged twice at 16,500 rpm and 4 °C for 20 min. The supernatant 
fraction was loaded onto a 10 ml affinity chromatography Ni-NTA column (GE Healthcare) 
containing Ni2+ and previously equilibrated with lysis buffer. Elution of the retained proteins was 
achieved with a linear imidazole gradient (20 column volume, 10 mM-400 mM). 
Fractions containing protein eluted from Ni column were concentrated (Centricon Plus 
centrifugal filter units; Millipore) to 2 mL, and loaded onto the gel filtration column (HiLoad 
16/60 Superdex 200 pg. GE Healthcare), which was equilibrated with gel filtration column 
buffer (300 mM NaCl, 50mM HEPES, pH 7.5). 
The YzcR concentration was determined with the Bio-Rad protein assay kit. The protein 
molecular weight was analyzed using Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE). Purified YczR protein was used freshly after exchanging into 
suitable buffers for the crystallization and biological assays. The YczR protein was stored with 
high salt concentrations (300 mM Nacl) and 5 % imidazole to stay soluble without precipitation. 
The protein was stored at 4 °C for short-term or flash frozen in1000µL aliquots in liquid nitrogen 
after the addition of 20% (V/V) glycerol and stored at -80°C for long-term use. The color of 
concentrated, purified YczR was pale yellow because PLP was bound to the protein. 
Crystallization. The purified YczR was buffer exchanged into crystallization screening 
buffer (50 mM HEPES, pH 7.5, 300 nM NaCl) and concentrated to 10 mg/ mL using a 10,0000 






sparse matrix screen (Crystal Screen Cryo 1 and 2, Crystal Screen 1 and 2, Index 1 and 2, and 
PEG/Ion 1 and 2 from Hampton Research and Wizard 1&2 and 3&4 from Emerald BioSystems) 
were set up with the Gryphon crystallization robot (Art Robbins Instruments) to obtain initial 
crystallization hits. 
Crystals appeared in the well solution containing 20% (W/V) PEG8000, 100 mM HEPES, 
pH 7.5, 200 mM (NH4)2SO4, and 10% (V/V) isopropanol after a week during incubation at room 
temperature. After the initial crystallization screen, Crystals of YczR were obtained via the 
sitting drop methods incubated at room temperature. Further optimized manually using a 1:1 well 
solution: YczR stock solution (10 mg/mL) ratio to obtain crystals with the best size and 
morphology. Crystallization was conducted in 24-well Cryschem sitting drop plates (Hampton 
Research). Crystals grew to maximum size in 1-2 weeks and were harvested in about 15 days.  
For attempted co-crystallization of YczR and L-alanine, 6 µL of YczR (20 mg/mL) was 
mixed with 1 µL of 10 mM L-alanine (dissolved in protein crystallization buffer) with 4 µL of 
well solution containing 8% (V/V) Tacsimate, pH 6.0, 20% (W/V) PEG8000. Crystals were 
seeded on day 3 with crystals obtained from previous trials. Crystals with good size and 
morphology were picked directly from the sitting drops into a cryoprotecting solution (well 
solution supplemented with 25% (v/v) glycerol) and then flash-cooled in liquid nitrogen.  
X-ray Diffraction Data Collection. Individual YczR crystals were flash frozen in liquid 
nitrogen using 30% PEG10,000 in the crystallization buffer as a cryoprotectant solution. The 
diffraction data of YczR were collected at Advance Photon Source (Argonne National 






YzcR crystal diffraction images were recorded by the 4×4 tiled 300×300 mm2 sensitive area 
CCD detector from Area Detector Systems Corp. (ADSC). The data collection was at a 
wavelength of 1.0 Å. The datasets were indexed, integrated and scaled using the HKL2000[74].  
Structure Determination, Model Building, and Refinement. The collected datasets were 
all scaled in the space group C2221 to a resolution of 1.79 Å. Auto build by molecular 
replacement using PHASER[75] in the PHENIX[76] software suit automatically built about 60% of 
the residues. Manually build the remainder of the model in COOT[77]. Rigid body refinement 
followed by restrained refinement was carried out in Refmac5 in the CCP4 software suits until 
no more side chains can be built in automatically[78]. Final refinement statistics of YczR are 
listed in Table 1. Structural figures were made using UCSF Chimera[79]. 
UV-Absorption Spectroscopy. UV-Vis absorption spectra were recorded with Jasco V-
550 spectrophotometer in 1 mL quartz cuvettes in 50 mM Tris-HCl, pH 7.5, and 300 mM NaCl 
at 25 °C. The enzyme solution was centrifuged 5 mins at 14,000 RPM to reduce light scattering 
from the small amount of precipitate. The protein solution contained 10 mM potassium 
phosphate buffer at pH 7.5. 
Absorption of YczR-PLP (7 µM) with L-alanine (50 mM) was observed in the UV range 
300-600 nm over time. Also measure YczR-PLP (7 µM) at various with 300 mM Β-Alanine, L-
serine, Arginine, Lysine, Tyrosine, Histidine, Aspartic acid, Phenylalanine, Leucine, Proline, 
Threonine, Valine, GABA, Tryptophan, Asparagine, Methionine, and Glutamine separately as 






End-point Assay to Monitor the YczR Catalyzed Half Transaminase Reaction. 
Activity was measured using varying concentrations of YczR protein in an assay buffer 
containing 50 mM HEPES (pH 7.5), 300 mM NaCl, 500 mM L-alanine, 320 µM NADH, and 5 
units Lactate dehydrogenase (LDH). 
In the first half-reaction, add 1 µM, 3 µM and 7 µM YczR to 500 µM L-alanine overnight at 
room temperature. In the coupled assay, measure the amount of pyruvate produced from each 
tube. LDH consumes the product of the first half-reaction (pyruvate) to produce lactate. The 
coupled reaction is measured spectrophotometrically (absorbance change at 340 nm) from the 
concomitant oxidation of the cofactor, NADH to NAD+. 
Fluorescence emission spectroscopy. Fluorescence emission spectroscopy is a type of 
electromagnetic spectroscopy, which analyzes fluorescence from a sample. Experiments were 
performed using a PTI Quanta-Master fluorimeter (Photon Technologies, Mirmingham, NJ). 
Time-based assays were conducted with excitation and emission wavelengths set at 283 and 326 
nm, respectively. The measurement was initiated after 1.4 µM YczR-PLP and in the presence of 
500 mM L-alanine in the buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl. 
Fluorescence emission spectra were measured every 4 mins from 0 min to 20 mins at 25 °C. 
GraphPad Prizm 3.0 was used for analyzing the time-dependent curves. 
Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS). The 
size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) was used 






with the AKTA FPLC system (GE Healthcare Biosciences) with a silica-based size-exclusion 
chromatography column (WTC-030S5, Wyatt Technology) as a liquid chromatography unit. 
For the experiments, the column was connected upstream of a refractive index detector 
(Optilab TrEX, Wyatt Technology), and then followed by a multiangle light scattering detector 
(Dawn Heleos II, Wyatt Technology) used for determining protein concentration and particle 
size, respectively.  
SEC-MALS sample injection requires 100 µl of a solution containing 7 µM YczR protein in 
50mM HEPES (pH 7.5), 300 NaCl buffer. The flow rate was set at 0.4 mL/min, and data were 
collected at 2 s intervals. Data processing and analysis were performed by the ASTRA software 
(Wyatt Technology). 
Fluorescence Polarization Assay. The binding affinity of YczR for a DNA containing the 
68-bp YczR binding site was determined by fluorescence polarization assays[70]. Synthesis 
Labeled DNA Sequence with fluorophore from Integrated DNA Technologies (IDT)  
Two 68-bp complementary single-stranded DNA oligonucleotides containing the YczR 
binding region (5'- TTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGG 
ACTGATAATTAATGGCCAGTTTT-TAMRA3', where Fl means fluorophore) were purchased 
from Integrated DNA Technologies (IDT).  
Based on the four direct repeats on the DNA sequence, two 34-bp complementary single-
stranded DNA oligonucleotides containing the YczR binding region (5'- TTTCCTCAACAT 
CATTGCGAATGCCCTCATCATC-TAMRA-3') and (5'-AAAACTGGCCATTAATTA 






Both oligonucleotides were synthesized and labeled with the fluorophore, 
carboxytetramethylrhodamine (TAMRA) attached at the 3' terminus. TAMRA has an emission 
maximum of 580 nm and an absorbance maximum of 565 nm. 
The double-stranded oligonucleotides were prepared by annealing a mixture containing an 
equimolar concentration of the two single-stranded oligonucleotides at 25 µM in 10 mM Tris-
HCl, pH 8.0, 1 mM EDTA, and 50 mM NaCl. The annealing solution was heated at 90°C for 1 
minute, and then cooled 5°C per minute until it reached 10°C by using a Mastercycler Personal 
(Eppendorf). 
For the fluorescence polarization assay, YczR was serially diluted in the buffer (50 mM 
HEPES, pH 7.5, 5% Glycerol, 300 mM NaCl) to acquire the appropriate concentrations against a 
fixed concentration of TAMRA-labeled DNA (1 nM). 
The constant concentration (0.1 nM) of TAMRA-labeled DNA was mixed with the serially 
diluted YczR protein (final concentration, 0-1,000 nM). The DNA binding reaction contained 50 
mM HEPES, pH 7.5, 10 mM MgCl2, 0.1 µg/µL BSA, 100 mM NaCl, and various concentrations 
of protein typically in 100 µL. The sample mixture was loaded into the individual wells of a 384-
well micro-plate. Fluorescence polarization data for the YczR DNA complex were obtained 
using a BioTek Synergy 2 Plate Reader (BioTek). The fluorescence polarization (FP) signals of 
the YczR-DNA mixtures were measured with fixed excitation (531 nm) and emission (595 nm) 
wavelength filters at room temperature. In the negative control binding assay, Add Bovine serum 







The change plots in mP as a function of YczR concentration were used to determine the 
equilibrium dissociation constant (Kd) for the interaction between YczR and DNA binding site. 
The data was fit to a hyperbola using the program Kaleida Graph (Synergy Software). Determine 
Kd by: (Bmax)([S])/Kd+[S], where Kd and Bmax are derived from the single-ligand binding 
plot, and [S] is the concentration of the fluorescein-labeled DNA. Use the Kd result to calculate 




CONCLUSIONS AND FUTURE INVISTIGATIONS 
Many widespread DUFs are biologically essential in bacteria, and the importance of 
understanding and prioritizing DUF research has been recognized in the last few years[80]. DNA 
sequence alignment results have indicated that YczR in K. pneumoniae is the transcriptional 
regulator of YczE (DUF161) a new MocR/GabR subfamily member of the GntR superfamily.  
In this study, we have defined two X-ray structures of the YczR regulation domain: a 1.79 
Å structure with PLP bound and a 2.0 Å apo structure without PLP.  
To the best of our knowledge, these structures are the first YczR X-ray crystal structures 
solved. The elucidation of the three-dimensional YczR crystal structure provided important 
information regarding the structure-function relationship and domain arrangements of the 
MocR/GabR subfamily. Additionally, this information allowed for transcriptional activity 
analysis of YczR.  
GabR is the best genetically and biochemically characterized MocR/GabR subfamily 
member. The members of the MocR/GabR subfamily contain an N-terminal wHTH DNA-
binding domain and a C-terminal aminotransferase-like PLP binding domain. YczR and GabR 
belong to the same evolutionary subgroup the MocR/GabR subfamily and share similar 







The N-terminal helix-turn-helix DNA-binding domain was not found in the two YczR 
crystal structures. However, SEC-MALS and mass spectrometry results suggested that the YczR 
protein is full length in solution after purification. We speculated that YczR lost the DNA-
binding domain during crystallization, likely due to a contaminated protease activity. Although 
YczR and GabR are similar in molecular weight, the SAXS results indicated that YczR occupies 
a greater volume. We surmise that the interactions between the DNA binding domain and the 
regulation domain within YczR are weaker than in GabR. This allows for full extension of the 
linker region, which contributes to the loss of the DNA binding domain during crystallization.  
Similar to GabR, YczR has a co-factor, PLP, which is a common co-enzyme among a large 
number of enzymes. Also, like GabR[36], the YczR structure shown indicates that the ε-amino 
group of lysine331 forms a covalent Schiff base linkage (internal aldimine) with the aldehyde 
group of PLP; which serves as the only effector of the YczR. In contrast, GabR requires GABA 
for modulation of its activity in addition to PLP[54]. Based on Belitsky’s publication, the 
intracellular level of PLP in bacteria is most likely not subject to significant variations[54]. It is 
unusual among bacterial transcriptional regulators to require a B6 vitamin for activity 
modulation.  
YczR is a likely DNA-binding transcription regulator that requires the presence of PLP for 
activation of the yczE promoter. YczR binds DNA sequence between yczR gene and yczE gene 
in similar fashion comparing to GabR. From the fluorescence polarization results, it appears that 
an oligomeric form of YczR binds to two binding sites within the yczE gene. The YczR can 






YczR likely binds to the regulation region with a 2:1 stoichiometry. The dissociation 
constant (Kd) of the YczR-DNA complex was determined to be 26.47 nM. Although the precise 
stoichiometric binding of YczR for DNA is unknown, the dissociation constants which been 
determined from the fluorescence polarization assay suggest that YczR binds DNA with a high 
affinity. Four direct repeats of the sequence CCTCA and AATGG were located in this fragment, 
which appears to be essential for YczR binding. YczR binds tighter to the site closer to the yczE 
gene. 
YczR regulation domain catalyzes a reversible half-transaminase reaction instead of being a 
non-enzymatic regulator like GabR. The only documented role of PLP as a cofactor in numerous 
enzymes is catalytic[81]. As such most of the aminotransferases are involved in the metabolism of 
amino group-containing compounds [42, 45]. It seems likely that PLP plays the same type cofactor 
role in YczR as it does in GabR. The aminotransferases PLP-binding domains evolved 
specifically to catalyze the aminotransferase reaction[46, 82, 83]. The UV-visible spectrum and 
fluorescence emission spectra results suggested the possibility that the regulatory domain of 
YczR maybe positive regulation of transcription because it could catalyze the half enzymatic 
reaction involving PLP.  
Previous research efforts have shown that potent mechanism-based in-activators can be 
rationally designed against these PLP-dependent drugs-targets. Although the mechanistic 
function of PLP cofactor has been studied in details, its transcriptional regulator role has not 
been fully elucidated[54]. Our current research results will contribute to understanding the role of 






functions for the 330 amino acids long PLP-binding aminotransferase-like regulator domain of 
YczR can be suggested: (1) it has a structural role to maintain oligomerization overall and/or 
stability; (2) it is an effector-binding domain; (3) it likely performs an enzymatic reaction 
unrelated to regulatory functions and the DNA-binding of YczR; it may catalyze an enzymatic 
reaction, which is essential to exert its regulatory functions of YczR. 
PLP also may interact covalently with taurine to activate TauR[55]. YczR likely responds to 
alanine to regulate taurine trafficking in K. pneumoniae to facilitate infection in animals and 
humans.  
Taken together, all the results from UV absorption and half alanine-glyoxylate transaminase 
assay indicate that the YczR is highly specific for catalyzing L-alanine to pyruvate processing, 
thereby playing a pivotal role in L-alanine detoxification. In this half-reaction, the L-alanine 
reacts with PLP and transfers its α-amino group to PLP to make pyridoxamine phosphate (PMP). 
A new Schiff base is generated once the L-alanine interacts with the PLP commonly referred to 
as the external aldimine[36]. If in the complete transaldimination reaction, then PMP would 
transfer its nitrogen to the sugar to make an amino sugar. However, the crystal structure of YczR 
showns that PMP had been released from the regulation domain active site pocket.  
 L-alanine could have specificity affected to YczR-DNA interaction. It may affect YczR-
DNA interactions though PLP. The use of a variety of biochemical techniques has allowed us to 









 YczR monomer’s molecular weight is 52.2kDa. YczR should be full-length protein in 
solution depend on mass spectrometry result. To research the selectivity and reaction 
mechanisms of YczR, future studies could involve active site residues mutations in YczR. Full-
length YczR is not very stable at room temperature and low salt concentration solution. DNA 
binding domain of YczR would be moved to make truncated YczR protein.  
DNA foot printing is a method to determining the DNA sequence specificity of DNA-
binding proteins binds in vivo or in vitro. YczR is the transcriptional activator controlling the 
transcription of YczE (DUF161). The localization of YczR DNA binding sites would elucidate 
the function of YczE.  
Many years of the alarming rise of bacterial resistance and antibiotics abuse has created a 
dangerous quandary for antibiotics research. Advances in the development of the scientific 
technology, and more tools have been provided for the improvement of the already established 
antibiotics and the new antibiotic classes discovery. The research of YczR maybe used to design 




THE AQUEOUS DECAY OF A VANADIUM COMPLEX SEREDIPUOSLY REVEALS 
MISSING KNOWLEDGE ON THE REDOX STATES OF PTP1B 
Research aims: The decay of a vanadium complex and its redox effect on PTP1B, a target 
for diabetic treatment, in vitro 
Diabetes is the seventh leading cause of death in the United States in 2016. The Center of 
Disease Control (CDC) and the American Diabetes Association (ADA) published the Diabetes 
Report Card in 2014, stating that 29.1 million Americans are diagnosed with diabetes as of 
2012[84]. There are two major types of diabetes with , which people are diagnosed, type 1 and 
type 2.  
Type 1 diabetes is genetically inherited and occurs when insulin is not produced in 
sufficient quantities. In type 2 diabetes, the insulin is produced in standard quantity, but the 
insulin receptors are desensitized and unable to transmit the signal inward to the cell[85, 86]. Type 
2 diabetes is often seen in patients with unhealthy lifestyles and is of interest due to the 
prevalence of patients with heart disease[87]. 
Protein-tyrosine phosphatases (PTPs) are a class of enzymes that regulate a variety of 
fundamental cellular processes[88, 89]. PTP1B is a critical negative regulator of leptin signaling 
pathways[90, 91]. Protein Tyrosine phosphatase 1B (PTP1B) was the first PTP purified from 






Previous studies have indicated that PTP1B plays an important role in cell signaling 
relevant to diabetes, obesity, and cancer[92-94]. PTP1B is a critical negative regulator of leptin 
signaling pathways[90, 91]. PTP1B also is a key negative regulator of insulin signaling pathways, 
which inhibit the pathway responsible for controlling the uptake of glucose into the cell and 
lowering blood sugar levels[95]. Inhibition targeting PTP1B could prove to be effective in the 
treatment of type 2 diabetes and provide an opportunity to improve insulin sensitivity[84, 96]. 
However, the difficulty lies in identifying a specific, potent and safe PTP1B inhibitor. The two 
major challenges in developing potential therapeutics targeting PTP1B are lack of selectivity 
over other similar PTPs as well as lack of cell permeability[97]. Developing PTP1B inhibitors 
should simultaneously occupy both active site (Site-A) and the adjacent pTyr binding site (Site-
B) partially to address the selectivity issue[98].  
Vanadium compounds have been known to be insulin-enhancing agents both in vitro and in 
vivo[99]. Orthovandate (VO43-), the vanadate form which most closely mimics PO43-, can act as a 
substrate analog to inhibit all types of phosphatases because it shares similar structural properties 
with phosphorus[100].  
Organic vanadium complexes have been proven more effective in vivo and in vitro studies 
than inorganic vanadium compounds[101]. It has been demonstrated that the peroxovanadium 
compounds irreversibly oxidize the thiol group of the conserved catalytic cysteine in the PTP 
catalytic sites[102]. Various vanadium compounds may have a different but overlapping spectrum 
of PTP inhibition activities, due to differences in their structure and stability. Vanadium is not 






because of the favorable membrane permeability[99, 103]. The detailed mechanisms by which 
different vanadium complexes enhance insulin’s activity are still not fully understood[104, 105].  
Another specific product generated during this decay and their effects on PTP1B was not 
looked at carefully. The prevalent explanation is that vanadium compounds would break down in 
solution and inhibit PTP1B activity via the generated vanadate acting as a transition state analog 
in the PTP1B reaction[102, 106, 107].  
Vanadyl acetylacetonate, VO(acac)2 is an organo-vanadium complex, where (acac) is the 
conjugate base of acetylacetone[108]. VO(acac)2 has been shown to inhibit tyrosine phosphatases 
(PTPases), such as PTP1B[107]. Like other charge-neutral acetylacetonate complexes, it is more 
soluble in polar organic solvents. 
This work will focus on the co-crystallization and inhibition of PTP1B using synthesized 
VO(acac)2 complex (Figure 33). In addition to vanadium complexes having shown potential in 
the treatment of Type 2 diabetes, other studies indicated shown that some zinc complexes also 
have similar insulin-enhancing effect in treatment of type 2 diabetes[109].  
Besides the drug design effort, the oxidation state of the catalytic cysteine in the PTP1B 
activity down regulation still presents some unsolved puzzles. Robin Carr & Harren Jhoti found 
that after soaking PTP1B with 2-phenl-sioxazolidine-3, 5-dione, the sulphur Sγ atom of Cys-215 
formed a covalent bond with the backbone nitrogen atom of Ser-216[110]. In our studies, it was 
observed that while Cys-215 was oxidized; it did not form a covalent bond with the backbone 
nitrogen atom of Ser-216, representing a possible intermediate state in redox sensing.  






crystallization experiment of PTP1B and VO(acac)2. In addition to the inhibited structure via a 
vanadate species, the catalytic Cys-215 is shown to be partially oxidized and in two alternative 
conformations. Combining both inhibition studies and the crystal structures present important 
gap knowledge in the modification/oxidation of the PTP1B via the aqueous decay of VO(acac)2.  
 






Results and Discussion 
A variety of structural, enzymatic and kinetic studies from several laboratories have made 
clear that the mechanism of PTPs substrate recognition and catalysis[111-113]. All members of the 
PTPs are characterized by the presence of a signature motif, which contains the cysteine residue 
(Cys-215 in PTP1B) that is essential for catalysis[112]. PTP-mediated catalysis proceeds via a 
two-step ping-pong mechanism (Scheme 2).  
 
 
Scheme 1. The general mechanism of the PTP-catalyzed reaction. The WPD-loop assumes a 
catalytically active closed conformation with the general acid in position to protonate the leaving 
group during formation of the phosphor-enzyme intermediate. In the second step this 
intermediate is hydrolyzed. After the phosphate product is released the WPD-loop open 






In the first step, a nucleophilic sulfur atom of the thiolate side chain of the cysteine attacks 
the phosphate ester moiety of the substrate, resulting in the formation of a phosphor-enzyme 
intermediate with the release of the peptidyl-tyrosine. The second step occurs via the 
phosphoenzyme intermediate attacked of a water molecule, which mediated by Asp-181 and 
Gln-262, yields the final products inorganic phosphate and the regenerated enzyme.  
Structure of PTP1B and VO(acac)2 Complex 
The X-ray structures for PTP1B in the presence of the competitive inhibitor vanadate was 
determined by molecular replacement and refined to a 2.2 Å resolution. Overlapping X-ray 
crystal structures of PTP1B as ribbon diagram with VO(acac)2 as a ribbon diagram is shown 
(Figure 34). 
The PTP1B crystal structure to be solved was that of the 37kDa PTP1B catalytic domain 
with VO(acac)2 complex. PTP1B is one of the 38 classical PTPs that specifically target 
phosphorylated tyrosine residues. It is composed of an N-terminal catalytic domain, two proline-
rich motifs, and a C-terminal hydrophobic region. The crystals belong to P21 space group with 
cell dimensions (a= 52.17 Å, b = 71.75 Å, c = 88.01 Å) diffracted to 2.2 Å. The vanadium 








Figure 2. Overlapping X-ray crystal structures of PTP as ribbon diagram 1B with VO(acac)2 as a 
ribbon diagram. 
The electron density of residues revealed the presence of covalently bound Vanadate in the 
pocket situated at the interface of the subunits in the crystal structure of PTP1B (Figure. 35). It is 
of interest to note that the structure of the initial Vanadium complex had degraded before the 
actual binding of the inhibitor to PTP1B. The pocket also corresponds to the cofactor binding 







Figure 3. Electron density of the vanadate modified catalytic cysteine. Vanadate is shown with 







Table 2. Crystallographic data collection and refinement statistics for PTP1B 
 PTP1B 
Space group P21 
Cell dimension  
α, β, γ (deg) 60.743, 61.26, 88.307 
a, b, c (Å) 90.0, 90.041, 90.0 
Resolution (Å) 1.83 
Resolution at I/σ (I) =2 1.90 
Rpim a (%) 5.8(43) 
I/σ (I) 12.3(8.3) 
CC ½ b 0.673 
Completeness (%) 91.1(83.4) 
Multiplicity  
No. Reflections  
No. Unique Reflections  
  
Rwork c/Rfree d(%) 17.7/22.6 




B factors (Å2)  
protein 29.135 
ligand  
RMSD e  
bond lengths (Å) 0.02 
bond angles (deg) 1.96 
Ramachandran plot (%)  
most favored  
allowed  
outliers  
aPrecision-indicating merging R 
bPearson correlation coefficient of two “half”data sets 
cRwork = Σ|Fobs − Fcalc|/ΣFobs 
dFive percent of the reflection data were selected at random as a test set, and only these data were used to calculate Rfree 








The Electron Density in Green is the simulated annealing omit difference map (2Fo-Fc), at 
1.0 sigmas, that shows the existence of orthovanadate (VO43-). The central vanadium atom of 
orthovanadate is covalently linked to the sulfate of Cys-215. The Electron Density in grey is the 
simulated annealing composite map (2Fo-Fc) showing sulfenic acid, which is oxidized at the 
Cys-215 residue and exists in 2 positions at 1.0 sigma.  
From the omit map, the thiol group on Cys-215 has been oxidized. The side chain exists in 
two conformations, with one bound to Vanadate and the other facing out of the active site. 
Presently, the oxidized Cys-215 remains active. VO(acac)2 forms Electrostatic interactions with 








Figure 4. Electrostatic interactions between the VO(acac)2 inhibitor and the PTP1B active site. 
The hydrogen bonds between inhibitor and PTP1B are indicated by dashed lines. The crystal 
structure of the PTP1B: VO(acac)2 complex confirmed these noncovalent interactions. 
Electrostatic interactions between the VO(acac)2 bound Cys-215 and the PTP1B active site 
loop are shown (Figure 36). In the PTP1B covalent modification vanadium oxide (CVO) 
formation, the oxygen atoms in the modified Cys-215 forms two hydrogen bonds with the side 
chain hydroxyl of Ser-222 and the backbone amide of Arg-221; one of the oxygen atoms of 
vanadate forms hydrogen bonds with the backbone amides of Gly-220, Ile-219 and Gly-218. The 






water molecule, which interacts with the third oxygen atom of vanadate. The fourth oxygen atom 
forms hydrogen bonds with the backbone amide of Ser-216. In the sulfenic acid formation, the 
oxygen atom in the modified Cys-215 forms one hydrogen bond with the backbone amide of 
Ser-216.  
Previous work by Robin Carr & Harren Jhoti[110] found in the oxidized PTP1B active site, 
the sulphur atom in the Cys-215 has formed a covalent bond with the backbone amide of Ser-216. 
A crystallographic soaking experiment of PTP1B with one identified inhibitor (2-phenyl-
isoxazolidine-3, 5-dione) formed a sulphenyl-amide derivative of Cys-215. The sulphur Sγ atom 
of Cys-215 formed a covalent bond between the backbone nitrogen atom of Ser-216[110] (Figure 
37, B). The oxidation of catalytic Cys-215 formed sulphenyl-amide formation, which is a 
protective intermediate in the oxidative inhibition of PTP1B and caused significant changes in 







Figure 5. Superimposed images of sulphenyl-amide PTP1B (PDB: 1OES) (purple, A) and 
VO(acac)2 inhibition of PTP1B (green, B) show structural changes in the catalytic Cys-215 
active site. With VO(acac)2 inhibitor bound, the Sy atom of Cys-215 flips away from the 
backbone nitrogen atom of Ser-216 and can no longer form a sulphenyl-amide bond. 
In the previous research, after the oxidation of Cys-215 to sulphenic acid, the nitrogen atom 
of Ser-216 on the backbone nucleophilic attacked the Sγ atom of Cys-215 and formed a 1.7 Å 
covalent bond[110]. However, in the vanadate bound Cys-215 crystal structure of PTP1B sulfenyl-
amide formation, the distance between the Sγ atom of Cys-215 and the nitrogen atom of Ser-216 
was 2.9 Å, which suggested hydrogen bond formed (Figure 37, A). The present structure 
identifies an intermediate of their proposed mechanism of inactivation. This study provides 







Figure 6. Superimposition of the oxidation state structures of the PTP1B catalytic cysteine. The 
structure of the sulphenic acid derivative of Cys-215 is shown in blue (A). The structure of the 
VO(acac)2 derivative is in green (B). The phosphate binding cradle structure is largely conserved 
with VO(acac)2 bound to the catalytic cystine. 
The structures of key residues at the active site of the VO(acac)2 derivative are very similar 
to the structure of the sulphenyl-amide derivative oxidation states (Figure 38). And the structures 
of these oxidation states are very similar to the structure of reduced PTP1B. The vanadate bound 
Cys-215 intermediate is stabilized by the similar interactions observed for the oxygen atoms in 
the sulphenic acid derivate. However, in the sulfenic acid derivative, the side chain of A Cys-215 






The movement of the WPD-loop (a conserved protein loop) is important in the PTP1B 
catalyzed reaction. The WPD-loop has a “closed” and an “open” two distinct conformation. The 
WPD-loop would fold over the active site and bring the conserved Asp residue up to 8 Å closer 
to the bound substrate. The WPD-loop has negligible interaction with the P-loop in the “open” 
conformations[114-117]. The Vanadate also may reduce the mobility of the WPD-loop, which may 
decrease catalytic activity. 
 
Figure 7. Overlay of the WPD-loop open vanadate-bound (green) and the WPD-loop closed 
conformations in the active sites of the PTP1B enzymes. The trigonal bipyramidal structure of 
the vanadate anion is formed by a nucleophilic attack on the catalytic cystine. This also results in 







Different from Johnson’s result[112], in the crystal grown in the presence of vanadate, a 
WPD-loop open vanadate-bound form conformation is observed. The conformational differences 
between the open and closed conformations in the WPD-loop and the side chain of Arg-221of 
the PTP1B in both the ligand-bound and ligand-free states had been shown (Figure 39).  
In the WPD-loop open vanadate-bound form (Figure 39, B), the bound vanadate exhibits a 
trigonal bipyramidal conformation with apical positions occupied by the sulfur atom of Cys-215 
and an oxygen atom from a water molecule. Compared with the WPD-loop closed form (Figure 
39, A), the side chain of Arg-221 is rotated about 70o around chi-3 and form a hydrogen bond to 
the Phe-179 carbonyl group. In both the open and closed forms, the side chain of Phe-179 is 
embedded into a hydrophobic pocket. Unlike the WPD-loop, the P-loop has no significant 
motion during catalysis[118]. The P-loop backbone residues align closely in both the ligand-bound 
and ligand-free states.  
Kinetic results of PTP1B with VO(acac)2 Complex 
The data obtained using VO(acac)2 complex as an inhibitor is shown in Figure 40. The 
kinetic data suggests a competitive mode of inhibition because the apparent Vmax decreases, 
while the apparent Km decreases, too. The concentration of vanadium complex varied from 0-
0.3333 uM. The initial kinetic parameters obtained without vanadium complex are Vmax= 0.007 
U/mM and Km= 2.8±0.1mM. After 16 hours, the PTP1B lost 2/3 activities compared with the 







Figure 8. Activity versus substrate concentration for PTP1B against pNPP2- in the presence of 
















Materials and Methods 
Materials 
Chemicals for PTP1B purification, crystallization, assays were purchased from Sigma-
Aldrich (St. Louis, MO), Alfa Aesar (Tewksbury, MA) and Fisher Scientific (Pittsburgh, PA). 
YczR gene was synthesized with codon optimization for E. coli expression from Integrated DNA 
Technologies (Coralville, IA). E. coli BL21 (DE3) cells and Turbo cells were purchased from 
New England BioLabs (Ipswich, MA). Bacterial growth media Luria-Bertani (LB) broth and 
antibiotics were obtained from Sigma-Aldrich. Crystallization screen solutions and other 
crystallization supplies were purchased from Hampton Research (Aliso Viejo, CA) and Emerald 
Bio (Bedford, MA). All other materials were purchased at the highest quality available. 
Methods 
DNA Cloning. The PTP1B DNA fragment was digested with NdeI and NotI and 
subsequently cloned into the expression vector pETite. Transform the pETite-kan-c-5His vector 
with full-length PTP1B insert into E. coli Turbo cells for plasmid storage. The PTP1B plasmid 
was determined that there were no mutations in the entire coding region by DNA sequencing. 
(DNA sequencing & Genotyping Facility, University of Chicago, Chicago, IL) The resulting 
plasmid PTP1B was transferred to competent E. coli BL21DE3 cells for protein production and 
purification.  
Protein expression and purification. The PTP1B protein was purified by using the intein-
mediated purification with an affinity His-tag system. E. coli BL21DE3 cultures were grown 






ug/mL). Induction of PTP1B expression was carried out at an OD600 reached 0.6-0.8 by adding 
IPTG to a final concentration of 0.5 mM. Cells were harvested after 16 h incubation by 
centrifugation at 8670 G and 4 °C for 15 min (Avanti J-E Centrifuge, Beckman Coulter). 
 The cell pellet was resuspended in Ni-NTA column wash buffer (what is Ni column 
buffer). Using sonication (Qsonica sonicators, Q500 Sonicator) to break the cellular wall, the cell 
debris was removed by centrifugation at 31000G and 4°C for 20 min. 
 Protein purification was purified using affinity chromatography (Ni-NTA, GE Healthcare). 
The Ni-NTA column was equilibrated with a wash buffer (50 mM NaH2PO4, 500 mM NaCl, 
and 10 mM imidazole, pH 7.5) and the PTP1B fusion protein was eluted from the column using 
wash buffer with imidazole (100 mM) 
The fractions protein was concentrated to 2 mL using a 10 kDa Amicon-Ultra centrifuge 
filter tube (Centricon Plus centrifugal filter units; Millipore). Further purified by size-exclusion 
chromatography (HiLoad 16/60 Superdex 200, GE Healthcare), which was equilibrated with gel 
filtration column buffer (300 mM NaCl, 50mM HEPES, pH 7.5). 
The protein concentration was determined with a Bio-Rad protein assay kit. The protein 
purity assessed by SDS-PAGE. Purified PTP1B protein was concentrated (Centricon Plus 
centrifugal filter units; Millipore) and flash frozen in 1000µL aliquots in liquid nitrogen after the 
addition of 20% (V/V) glycerol and stored at -80°C for long-term.  
Synthesis Specific compounds as potential PTP1B inhibitors. VO(acac)2 had been 
synthesized from vanadyl sulfate: VOSO4 + 2 Hacac → VO(acac)2 + H2SO4. The procedures 






was performed under a pure N2 atmosphere using standard Schlenk and air-free manipulation 
techniques. The vanadium forms a square pyramidal structure. After the reaction, the complexes 
are purified using recrystallization. 
Crystallization. The purified YczR was buffer exchanged into crystallization screening 
buffer (50 mM HEPES, pH 7.5, 300 nM NaCl) and concentrated to 10 mg/ mL using a 10,0000 
molecular weight cutoff (MWCO) Amicon-Ultra centrifugal filter device (Millipore). PTP1B 
and VO(acac)2 were pre-mixed before crystallization. The initial sparse matrix crystal screen was 
using the Gryphon crystallization robot (Art Robbins Instruments) to obtain initial crystallization 
hits, and further optimized manually to obtain crystals with the best size and morphology.  
After the initial crystallization screen, crystal optimizations of PTP1B were obtained by the 
hanging drop method using protein at 10 mg/mL at room temperature. The optimized 
crystallization solution contained 20% (W/V) PEG6000, 100 mM HEPES, pH 7.5, 200 mM 
MgCl2. The hanging drops were incubated at room temperature. Crystals appeared in 6 days and 
grew to maximum size in1-2 week.  
Crystals with good size and morphology were picked from the hanging drops and flash-
cooled in liquid nitrogen using 20% (w/v) glycerol in addition to the compounds of the reservoir 
solution as the cryoprotectant.  
Diffraction data collection, Structure Determination, and Refinement. Diffraction data 
of PTP1B crystals were collected at Advanced Photon Source Structural Biology Center (SBC) 
19ID and 19BM beamlines. (Argonne National Laboratory, IL). The crystal diffraction images 






Systems Corp. (ADSC). The data collection was at a wavelength of 1.0 Å. The datasets were 
indexed, integrated and scaled using the HKL2000[74]. The datasets were all scaled in the space 
group P21 to resolutions of 2.2 Å respectively.  
Using PHASER[75] from CCP4 program suite performed molecular replacement, using the 
previously reported PTP1B (PDB ID: 1BZJ) as the search model[117]. Rigid body refinement 
followed by restrained refinement was carried out in Refmac5 in the CCP4 software suits until 
no more side chains can be built in automatically[78]. 
The remainder of the model was built and modified manually in Coot based on electron 
density maps. Before built the ligand in the model, the electron density from the Fo-Fc map 
supported the existence of the modification of Cys-215. The chemical restraint of Vanadium 
compound was generated in the program JLigand from CCP4.  
The ligand was manually fit in the model based the residual electron density in the 
deference (Fo-Fc) map. The PTP1B with Vanadium ligand model was further refined in Refmac 
5. The R free and R factor for the inactivated structure were 0.226 and 0.177, respectively. The 
data collection and refinement statistics for the PTP1B are given in Table 2. All figures depicting 
crystal structures were prepared by using Chimera.  
PTP1B inhibition assay. The PTP1B assay was used Synergy H1 hybrid multimode 
microplate reader (Biotek, USA) with 96 well plates (Greiner Bio-one, Monroe, NC). The 
PTP1B assay was carried out in a continuous manner using para-nitrophenylphosphate (pNPP2-) 
as the substrate. The absorbance of the product para-nitrophenol (pNP) was measured at 405 nm 






50 mM HEPES (pH7.5), and 5 mM DTT, 300 mM NaCl for 5 min at 25 °C. The reaction that 
was followed is given in equation. 
                  pNPP2-(aq) + H2O(aq)  à  PO43- (aq) + pNP (aq) +H+ (aq) 
Calculate enzyme activity from the data. The assay was carried out at 25 °C using the 
substrate pNPP2- in the presence of 2 mM EDTA in a 50 mM Bis-Tris (pH 6.3) buffer, which 
provides a constant ionic strength over a wide pH range. 
Reactions were initiated by addition of enzyme into the microplate wells (final reaction 
volume of 300 uL). Inhibition constants (Ki) for PTP1B were determined by measuring initial 
rates of pNPP hydrolysis in the presence of a range of concentrations of inhibitor (0-3.33 uM) 
and [pNPP2-] (0-20 mM) at pH 6.3 and 25 °C. Kinetic parameters were determined by a fit of the 





PTP1B is one of the most studied PTPs and plays a critical role in the regulation of the 
insulin-signaling pathway[84, 114]. The highly charged PTP1B catalytic site contains the common 
structural motif of PTPs. In the research pertaining to inhibition of PTP1B, specificity issues 
with other PTPs still present significant challenges, because of the high homogeneity to other 
cellular PTPs. It also remains a challenge in medicinal chemistry to design inhibitors with 
relatively uncharged outer surfaces and hydrophobic regions. This design would allow the 
inhibitor to cross membranes while maintaining relative efficacy once inside cells.  
PTPs specifically catalyze the dephosphorylation of phosphotyrosyl residues of peptides 
and proteins[119-121]. Orthovanadate (VO43-) is a phosphate analog that can quickly adopt a 
trigonal bipyramidal structure and could bind as a transition state analog to inhibit the PTP1B[122]. 
Previous research has proved this part of vanadate’s insulin-mimetic effect due to its PTPs 
inhibition function[123]. 
Vanadate was reported to inhibit protein phosphotyrosine phosphatase and activate 
autophospohrylation of solubilized insulin receptors[124]. Vanadate is insulin-mimetic[125] , and its 
insulin-mimetic properties have been researched in details[107]. It has been shown to be 
potentially useful in treating both noninsulin- and insulin-dependent diabetes mellitus in human 
clinical trials[126]. Vanadate has multitudinous effects on biological systems[123]. The 






Vanadate may also have a strong affinity for the PTP1B active site[119-121, 128].  
Vanadate would chelate many organic molecules and also reversibly coordinate free thiol 
and hydroxyl groups. The interaction of vanadate with assay components and buffers has also 
been monitored in research investigating the mechanism of vanadate inhibition [106]. HEPES was 
chosen for the studies because it is one of the few buffers that does not have appreciable 
interaction with vanadate[106].  
After VO(acac)2 enters the cell, it would be degraded to vanadyl (IV) ion, and got oxdiated 
to vanadate (V)[129-131]. Furthermore, vanadate often was treated as a simple phosphate analog. Its 
rich redox and coordination chemistry also need to be considered, including coordination with 
many reagents and varied oxidation states[107].  
Here we report the X-ray structure of PTP1B with VO(acac)2 complex at a 2.2Å resolution. 
The detailed PTP1B crystal structure may provide more information about the ability of 
VO(acac)2 to bind the active site and inhibit PTP1B activity. The results suggest that the 
oxovanadium (IV) complex VO(acac)2 dissociates and oxidizes to a vanadium (V) species 
vanadate (VO43-) under crystallization conditions. This structure further suggests that better 
bioavailability of VO(acac)2 is the primary reason for its enhanced inhibitory behavior compared 
to simple salts[132].  
While the precise biochemical pathway of vanadate action is not yet known, these kinetics 
assay and X-ray crystallography studies will provide reliable proof of concept, validating the 
inhibition of PTP1B by VO(acac)2. Catalytic cysteine exists as a thiolate anion, making it 
susceptible to oxidation and more reactive. The mechanism of decrease regulating PTP1B 






Dithiothreitol (DTT) or glutathione can reduce the disulphides with Cys-215 to resore PTP1B 
activity[111].  
An essential cysteine residue at the catalytic site is the hallmark of PTPs. The cysteine 
would form a Thiol-phosphate intermediate during catalysis[133]. In this study, we set out to 
elucidate the mechanisms of vanadate inhibition of PTP1B. 
Compared with vanadium compounds, zinc compounds have received less attention in anti-
diabetic drug research. Zinc compounds also play essential structural roles in PTPs inhibition in 
vivo[134]. Previous research has shown that zinc compounds do not show inhibition of PTP1B at 
concentration lower than 10 uM[109].  
 Compared with previous research, this crystal structure also redefines the oxidation state of 
the catalytic Cys-215 in PTP1B. The nucleophilic Sg atom of Cys-215 attacks the backbone 
nitrogen atom of Ser-216 formed the sulphenyl-amide bond occurs through oxidation of Cys-215 
to sulphenic acid. The hydrogen bond interaction between the Nd1 atom of the invariant His-214 
side chain and the carbonyl oxygen atom of Cys-215 increases the partial charge on the 
backbone nitrogen atom of Ser-216 and enhance its reactivity. This assumption supports the 
nucleophilic substitution mechanism[114].  
During the in vitro oxidation reactions of the cysteine and thiol residues, sulfenic acids are 
commonly generated as intermediates[135]. We used a small organic vanadate molecule as a 
useful model to research the redox-sensing assembly of the PTP1B active site functional groups. 
The possible interactions and reactions of vanadate must be taken into consideration when these 






of inhibition of PTP1B, This would then aid in the design of potential inhibitors against the 
crucial therapeutic target of diabetes treating.  
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